Research shows that high expression of IGFBP-2 in 99 adult AML patients is associated with the upregulation of leukemia-related genes and poor prognostic markers, as well as an increased rate of drug resistance (176). This evidence concerns the gene IGFBP2 and acute myeloid leukemia.